Introduction {#S1}
============

Association between the G1 and G2 coding variants in the apolipoprotein L1 gene (*APOL1*) on chromosome 22q ranks among the most impressive genetic breakthroughs in complex disease.\[[@R1];[@R2]\] Idiopathic focal segmental glomerulosclerosis (FSGS), hypertension-attributed nephropathy, non-diabetic end-stage renal disease (ESRD), and HIV-associated collapsing glomerulopathy in African Americans are now recognized as one disease spectrum.\[[@R3]\] Significantly shorter kidney allograft survival in African-ancestry deceased donor kidneys also relates to presence of two *APOL1* risk variants, independent from donor race.\[[@R4]\] Nephropathy risk variants have been selected for based upon protection from Trypanosoma brucei rhodesiense, a cause of African sleeping sickness.\[[@R1]\]

However, not all individuals inheriting two *APOL1* risk variants will develop nephropathy. Additional genetic and/or environmental "second hits" are likely required to initiate kidney disease, interacting with *APOL1* risk variants to produce different renal histologic phenotypes.\[[@R5]\] HIV infection is clearly a second hit, typically producing collapsing FSGS with proliferation of podocytes.\[[@R6]\] Podocin gene (*NPHS2*) variants may also prove to be genetically-mediated second hits.\[[@R7]\]

The mechanism(s) underlying *APOL1*-associated nephropathy remain under intensive investigation.\[[@R8];[@R9]\] Aggressive blood pressure control and use of angiotensin-converting enzyme inhibitors failed to markedly halt progression of hypertension-attributed nephropathy to ESRD in the African American Study of Kidney Disease and Hypertension (AASK),\[[@R10]\] the kidney disease in AASK has subsequently been shown to be strongly *APOL1*-associated.\[[@R11]\] Without effective treatments and barring identification of treatable/preventable second hits, widespread screening efforts in the African American population are of unproven benefit. *APOL1* risk variants were associated with a higher prevalence of microalbuminuria and higher prevalence of a low glomerular filtration rate (GFR) in African Americans from the population-based Dallas Heart Study.\[[@R12]\] However, proteinuria and estimated GFR did not differ significantly between those with two versus less than two *APOL1* nephropathy risk variants. Close relatives of African Americans with non-diabetic forms of ESRD are at exceptionally high risk for developing nephropathy and disparate etiologies of nephropathy are often seen in these families.\[[@R13]--[@R20]\] Relatives are often considered for living kidney donation, as well.\[[@R21]\] This study assessed the association between *APOL1* nephropathy risk variants and risk of mild nephropathy in first-degree relatives of African Americans with non-diabetic ESRD.

Results {#S2}
=======

As of December 1, 2011, the Natural History of *APOL1*-associated Nephropathy Study recruited 826 African American children and siblings of index cases with non-diabetic ESRD and 786 have been genotyped for *APOL1* and ancestry informative markers. One individual was recruited in 249 families, two individuals in 137 families (N=274), and three individuals in 101 families (N=303). The mean (SD) median age at ESRD in the proband from families was 47.1 (13.4) 47.0 years. Adjusting for familial correlations, 23.1%, 46.7%, and 30.2% of genotyped relatives possessed two, one, or zero *APOL1* risk variants, respectively. [Table 1](#T1){ref-type="table"} contains demographic and clinical results in all 786 first degree relatives of ESRD patients, based on the number of *APOL1* risk variants. No statistically significant differences in renal or hypertensive phenotypes were observed in an additive model. [Figure 1](#F1){ref-type="fig"} displays the distribution of MDRD GFR and urine ACR based on genotypes.

*APOL1* associations with FSGS and non-diabetic ESRD best fit autosomal recessive inheritance. Therefore, unadjusted association analyses with *APOL1* nephropathy risk variants in categorical ([Table 2](#T2){ref-type="table"}) and continuous evaluation of renal phenotypes ([Table 3](#T3){ref-type="table"}) were performed using a recessive model. No evidence of association was observed in either of these analyses. Categorical classifications of GFR and urine ACR were based upon clinically relevant cut-points ([Table 2](#T2){ref-type="table"}).

*APOL1* association analyses were then performed in all 622 relatives without diabetes mellitus ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). A trend toward association was seen with urine ACR, but not with other phenotypes. Mean (SD) median urine ACR was 45.5 (257.4) 4.5 mg/g in those with less than two *APOL* risk variants versus 58.4 (172.8) 6.1 mg/g in those with two risk variants (p=0.1006). [Supplementary Table 2](#SD1){ref-type="supplementary-material"} contains the results of unadjusted association analyses limited to the 525 relatives not younger than five years before the age at ESRD in the index case from their family. This analysis was performed since younger patients destined to develop nephropathy may not yet display the phenotype. No significant associations were observed.

A series of multivariate analyses were then computed, adjusting for age, sex, age difference from age at ESRD in probands, and African ancestry. The results in all relatives are shown in [Table 4](#T4){ref-type="table"}, results limited to those without diabetes mellitus are shown in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}, and results in participants not younger than five years below the age at onset of ESRD in the index case are shown in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}. In these analyses, significant association was detected between *APOL1* and urine ACR ≥300 mg/g in the full sample (p=0.032, full-adjustment) and non-diabetic sample (p=0.032, full-adjustment); with a trend in the older age sample (p=0.065). Association was also observed with log urine ACR in the non-diabetic sample (p-value 0.050, full-adjustment); with a trend in the full sample (p-value 0.096). Strong and consistent trends toward association were seen with GFR using both MDRD and CKD-EPI equations in the full, non-diabetic, and older samples (p-values ranged from 0.050 to 0.0837, full-adjustment). In contrast, no significant evidence of association was observed for the dichotomous trait of kidney disease (defined as urine ACR ≥30 mg/g and/or MDRD GFR \<60 ml/min/1.73m^2^) or with urine ACR ≥30 mg/g.

Finally, suggestive evidence of diabetes by *APOL1* interaction effects on cystatin C concentrations was detected. The observed p-values ranged from 0.1321 to 0.1611 for Log (cystatin C), and from 0.0674 to 0.0895 for the dichotomous outcome of high vs. low cystatin C concentrations using a cutoff value of 0.96 mg/L. The interaction effect observed with the dichotomous variable reached statistical significance (p-value=0.0456) in the fully adjusted model after excluding all participants who were more than 5 years younger than their proband. Analyses stratified by diabetes status revealed a trend for a positive association between *APOL1* risk and high cystatin C levels in non-diabetic individuals (odds ratio 1.95; p-value=0.0565), and no effect in diabetic individuals (odds ratio 0.51; p-value=0.2927).

Discussion {#S3}
==========

Marked familial aggregation of non-diabetic ESRD is reproducibly observed in African Americans \[[@R13]--[@R19]\] and more than 30% of those initiating renal replacement therapy have close relatives already on dialysis.\[[@R20]\] Variation in the *APOL1* gene likely accounts for much of this phenomenon, displaying among the most impressive evidence of association in complex human disease. The present study revealed similar mean and median levels of albuminuria, serum cystatin C concentration, and estimated GFR among relatives of African Americans with non-diabetic ESRD, regardless of the presence of two or less than two *APOL1* risk variants. A high proportion of relatives with and without two *APOL1* risk variants had subclinical nephropathy. Multi-variable analyses accounting for age, sex, overall African ancestry, and age difference from age at ESRD in index cases revealed weak relationships between *APOL1* and urine ACR \>300 mg/g and with GFR \<60 ml/min per 1.73m^2^ with p-values ranging from 0.03--0.05, but not with lower levels of albuminuria (urine ACR ≥30 mg/g).

These data are reassuring in that *APOL1* associations between heavy proteinuria and reduced GFR were detectable in members of African American families at high risk for nephropathy. The 23% frequency of subclinical nephropathy in these relatives closely resembles frequencies reported in similar families recruited in Alabama.\[[@R18]\] Therefore, our families appear to be representative of such families in the southeastern U.S. The frequencies of urine ACR ≥30 mg/g and ACR ≥300 mg/g in these high risk families greatly exceeds those in the National Health and Nutrition Examination Survey III (NHANES III).\[[@R22]\] However, despite the high prevalence of silent kidney disease, our results suggest there may be limited value in the genetic screening of high risk first-degree relatives of African Americans with non-diabetic ESRD simply to detect those enriched for milder forms of nephropathy. In contrast to albuminuria and mildly reduced GFR, *APOL1* risk variants strongly associate with severe forms of nephropathy and ESRD. The majority of relatives with two *APOL1* nephropathy risk variants had a normal GFR without elevated urine ACR. In contrast, we previously demonstrated the potential benefit in screening African American deceased kidney donors for these risk variants.\[[@R4]\] It remains possible that *APOL1*-associated renal diseases may progress more rapidly to overt proteinuria (rendering microalbuminuria less helpful) and/or *APOL1*-associated microalbuminuria might be hard to identify in a population with more frequent metabolic-syndrome associated microalbuminuria. The families in this study are a unique high genetic/high environmental risk population, likely different from the general population. Longitudinal follow-up is currently underway to determine risk of progressive nephropathy in family members. In addition, 8 relatives with ESRD (\<1% of the study population) were excluded, potentially limiting our ability to detect association with severe kidney disease.

The frequencies of two and one *APOL1* risk variants were 23.1% and 46.7%, respectively, in this high-risk cohort. This substantially exceeds the 12% and 39% frequencies in the general African American population.\[[@R1];[@R12]\] Current study participants had a mean (SD) age of 47.6 (13.4) years (median 49.0) and 22.9% (40/175) of those with two *APOL1* risk variants had kidney disease defined as an MDRD-GFR \<60 ml/min per 1.73m^2^ and/or urine ACR ≥30 mg/dl, compared to 21.1% (129/611) of those with fewer than two risk variants (p=0.63). The mean age at onset of ESRD in African Americans was 59.2 years in the 2009 U.S. Renal Data System report.\[[@R23]\] When limiting our analysis to association with an MDRD estimated GFR \<60 ml/min per 1.73m^2^, low GFR was present in 8% of those with two *APOL1* risk variants, compared to 7% with fewer than two risk variants (p=0.66). When considering albuminuria, urine ACR ≥30 mg/g was observed in 20.0% of those with two risk variants relative to 17.5% with fewer than two risk variants (p=0.45). We also observed urine ACR ≥300 mg/g in 7.4% in individuals with 2 risk variants relative to 4.1% in those with 0 or 1 copy of the risk variant (p=0.07). Differences in renal and hypertensive phenotypes were not seen when contrasting those with zero, one or two *APOL1* risk variants ([Table 1](#T1){ref-type="table"}). Accounting for familial relationships and adjusting for participant age, sex, age difference from ESRD onset in probands, and ancestry revealed evidence of association with urine ACR \>300 mg/g and GFR \<60 ml/min per 1.73m^2^, but not with low level albuminuria or the dichotomous kidney disease trait defined as urine ACR ≥30 mg/g and/or low MDRD-GFR.

Similar results were reported by Friedman et al. in the large population-based Dallas Heart Study.\[[@R12]\] In the Dallas Heart Study, non-diabetic African American participants had a mean (SD) age of 44.8 (10.3) years. Microalbuminuria and/or MDRD-GFR \<60 ml/min per 1.73m^2^ were observed in 19.2% of non-diabetic subjects with two *APOL1* risk alleles, relative to 6.7% of those with fewer than two risk variants. However, mean MDRD-GFR and urine ACR values were *similar* and within the normal range in participants from both groups. The major difference between our family-based results and the Dallas Heart Study is seen in those with fewer than two *APOL1* risk variants; far lower frequencies of kidney disease were detected in Dallas Heart Study samples relative to these high risk relatives of index cases with non-diabetic ESRD.

The present results and those of the Dallas Heart Study strongly support the concept of a second inherited or environmental "hit" required to initiate fall in GFR or development of albuminuria in those with two *APOL1* risk variants. Although approximately 70% of cases of idiopathic FSGS in African Americans is *APOL1*-associated, it appears that the majority of middle-aged African Americans with either one or two *APOL1* risk variants do not have kidney disease. Nonetheless, a tenfold increase in risk for FSGS and ESRD is observed in those with two *APOL1* risk variants. HIV infection is a strongly associated environmental second hit.\[[@R6]\] Fifty percent of those with two *APOL1* risk variants and untreated HIV infection will develop HIVAN, in contrast to the 18% explained fraction (or proportion of total risk) of idiopathic FSGS cases attributable to *APOL1*. Accounting for the recessive *APOL1* genetic effect is predicted to reduce the prevalence of HIV-associated collapsing glomerulopathy and idiopathic FSGS by 67% in the African American population.\[[@R6]\]

Based on the results in this high risk family-based study and the Dallas Heart Study, we suggest caution before embarking on widespread *APOL1* screening to detect mild nephropathy in the African American community. At present, it appears that recording a family history of ESRD and routinely measuring urine ACR and estimated GFR may be more effective tools for detecting asymptomatic mild nephropathy. This recommendation will change upon identification of novel treatments and/or remediable second hits that initiate nephropathy. The Natural History of *APOL1*-associated Nephropathy Study is now following these participants longitudinally. Those with two *APOL1* risk variants, with and without nephropathy, will be contrasted to detect interactive genetic risk variants and evidence of environmental exposures (*e.g.*, non-HIV viral infections) that may trigger progressive nephropathy in genetically susceptible individuals.

There are limitations to this report. By design, many of our participants were related and eight relatives who had ESRD were not included due to the study design (788/796 or 99% of available relatives were recruited). Most have had only a single visit and they are relatively young. The current cross-sectional data will give way to longitudinal data, and follow-up has begun. Some unaffected relatives will likely develop future nephropathy, while low level albuminuria may regress in others. These phenomena will occur in both the *APOL1* risk and non-risk groups. The Dallas Heart Study report also utilized cross-sectional data and a follow-up visit is planned. Familial data were addressed by applying GEE. We expected to see reduced GFR and/or albuminuria in the majority of subjects with two *APOL1* risk variants destined to develop ESRD by the age of 5 years before the age at ESRD in the index case from their family. An earlier age at ESRD has been reported in those with two, relative to one, relative to zero copies of the *APOL1* G1 variant (49±14.9 *v* 55.9±16.7 v 61.8±17.1 years, respectively; p=1×10^−6^).\[[@R24]\] The mean age of our participants approaches the age at ESRD in the G1 homozygous group from the Kanji et al. report. Additional strengths of our study were adjustment for genome-wide African ancestry, consideration of the age at ESRD in the index case from each family, and a relatively large sample size. Asymptomatic first-degree relatives of ESRD index cases are a unique resource, more difficult to recruit than prevalent dialysis patients.

In this era of personalized medicine, geneticists are understandably rushing to translate genetic association results in the clinical setting. *APOL1* demonstrates among the highest odds ratio for genetic association with severe kidney disease and ESRD seen in any complex disease. Nonetheless, the results of this report in African Americans multiplex ESRD family members at high risk for nephropathy, as well as in a large population-based study, support that the majority of middle-aged individuals with two *APOL1* nephropathy risk variants will not manifest clinical nephropathy. Efforts to detect second hits that facilitate the development and progression of nephropathy, particularly treatable environmental risk factors and gene-gene interactions, should aggressively be pursued in order to further our understanding of the pathogenesis of *APOL1*-associated nephropathy.\[[@R5];[@R7]\] There appears to be a role for screening African-ancestry donor kidneys and living donors for *APOL1* risk variants in order to gauge likelihood of long term allograft survival; however, additional studies on the effect of *APOL1* on allograft outcome and allograft or recipient selection are necessary.\[[@R21]\] *APOL1* has a strong effect on a wide range of non-diabetic forms of severe kidney disease in AAs. However, it has only marginal effects on mild perturbations in renal function and low level albuminuria. This observation may provide important clues to mechanisms of action. At present, caution should be exercised before screening African Americans for *APOL1* genotypes to predict risk of mild nephropathy. We note that 21% of the first-degree relatives of high risk African American ESRD families possessing zero or one *APOL1* risk variants also had subclinical nephropathy, a finding that reflects other, as yet unidentified, risk factors.

Materials and Methods {#S4}
=====================

Study Participants {#S5}
------------------

The "Natural History of *APOL1*-associated Nephropathy Study" recruited up to three siblings and/or children without ESRD (first degree relatives) per family of self-described African Americans with non-diabetic forms of ESRD, including nephropathy attributed to hypertension, FSGS, HIV-infection, or unknown cause in non-diabetic subjects.\[[@R8]\] Parents were not recruited, nor were siblings or children who had ESRD (on dialysis or a functioning kidney transplant). We excluded 8 participants who were diagnosed with ESRD during the screening visit. Eligible relatives who reported having diabetes mellitus were included. Siblings and offspring were eligible if they were no more than 15 years below the age at ESRD in the proband from their family (relatives older than the age at ESRD of their proband were included). Relatives were genotyped for *APOL1* nephropathy risk variants and genome-wide ancestry informative markers, which were used for individual ancestry proportion estimation. Fasting serum, ethylenediaminetetraacetic acid plasma, urine, buffy coat and DNA samples were collected and phenotyping performed for sub-clinical kidney disease and associated risk factors (*e.g.*, blood pressure, fasting blood sugar, body mass index \[BMI\]). Participants will be longitudinally evaluated in an attempt to detect the natural history of, and triggers for, *APOL1*-associated nephropathy.

Genotype Analysis {#S6}
-----------------

DNA extraction from whole blood was performed using the PureGene system (Gentra Systems, Minneapolis, MN). Two SNPs in the *APOL1* G1 nephropathy risk variant (rs73885319; rs60910145) and an indel for the G2 risk variant (rs71785313) were genotyped on the Sequenom (San Diego, California). In addition, 106 di-allelic ancestry informative markers (AIMs) were genotyped to determine population substructure. Samples included 44 Yoruba (YRI), 39 European American controls and the 786 African American study participants using Illumina Inc. Custom Genotyping Services (San Diego, CA) or the Sequenom Mass Array (San Diego, CA).

Laboratory Evaluation {#S7}
---------------------

Serum creatinine concentrations were measured using creatinase enzymatic spectrophotometry, blood urea nitrogen using the urease enzymatic assay, cystatin C using an immunoassay, and urine albumin: creatinine ratio (ACR) by microalbumin immunoturbidimetric methods at Laboratory Corporation of America (LabCorp; Burlington, North Carolina; [www.labcorp.com](www.labcorp.com)). Urine ACR values ≥30 mg/g were considered elevated (≥300 mg/g was considered overt proteinuria). Estimated GFR was computed using both the four-variable MDRD \[[@R25]\] and CKD-EPI \[[@R26]\] equations; MDRD GFR values \<60 ml/minute per 1.73m^2^ were considered abnormally low. A variable reflecting subclinical kidney disease based on urine ACR ≥30 mg/g and/or MDRD GFR \<60 ml/minute per 1.73m^2^ was employed, as in Friedman et al \[[@R12]\]. Normal values for cystatin C were \<0.95 mg/L.

Statistical Methods {#S8}
-------------------

Genotype frequency estimates were adjusted for familial correlation using McPeek's best linear unbiased estimator of allele frequency for pedigree data.\[[@R27]\] This estimate is given by (1*^T^K*^−1^1)^−1^1*^T^K*^−1^*X* where *1* is vector of ones, *K* is the expected kinship coefficient matrix, and *X* is the observed genotype at the G2 six base pair insertion deletion marker and rs73885319, one of the two G1 SNPs that are in perfect linkage disequilibrium. This estimate was multiplied by a factor of 0.5 to account for the fact that *APOL1* genotype is effectively a combination of the genotypes observed at these 2 markers.

We used the Wilcoxon two-sample test for comparing the distribution of all continuous outcomes between individuals who carry two copies of the *APOL1* risk variant and those who have zero or one copy (recessive coding), and its generalization, the Kruskal-Wallis test for comparing the observed distributions in the three genotypes (additive coding). Association with categorical outcomes was tested using Chi-square tests with the appropriate degree of freedom.

A series of generalized estimating equations (GEE) assuming exchangeable correlation and using the empirical estimate of the variance to adjust for familial correlation was computed to test for associations between renal phenotypes and *APOL1* risk genotypes.\[[@R28]\] This approach could lead to type I error inflation for markers with low minor allele frequency in more complex pedigrees. However, this approach is expected to perform well in this case, given the observed allele frequencies and study design including only first degree relatives. The Box-Cox method was applied to identify the appropriate transformation of each outcome variable that would best approximate the distributional assumptions of conditional normality and homogeneity of variance of the residuals.\[[@R29]\] Age, sex, age relative to age at ESRD in probands, and ancestry adjustments were incorporated, after an initial unadjusted analysis. These models were fitted using GFR, urine ACR, and cystatin C, respectively, as the outcome variable defined both on the continuous scale, as well as categorical variables using clinically meaningful cutoff values. Standard regression diagnostics for colinearity and influence were computed for each model reported. Finally, we tested for interaction effects between gender and *APOL1* status, and between diabetes status in relatives and *APOL1* on these outcome variables using the same set of covariates.

Supplementary Material {#S12}
======================
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###### 

Demographic and clinical characteristics of participants, based on the number of *APOL1* nephropathy risk variants

  Variable                       0 *APOL1* risk variants   1 *APOL1* risk variant   2 *APOL1* risk variants   P-value                                                                        
  ------------------------------ ------------------------- ------------------------ ------------------------- --------- ----- ------------- ------- ------ ----- ------------ ------- ------ --------
  African ancestry, %            231                       0.78±0.11                0.80                      0.12      375   0.78±0.11     0.80    0.13   175   0.79±0.09    0.80    0.13   0.7587
  Age, yrs                       234                       48.2±12.7                49.0                      18.0      377   48.0±13.7     49.0    19.0   175   45.6±13.5    48.0    17.0   0.1886
  Age relative to proband, yrs   233                       −1.5±9.0                 −1.0                      15.0      374   0.8±8.8       1.0     12.0   173   0.1±9.2      1.0     15.0   0.0181
  BMI, kg/m^2^                   233                       32.3±8.9                 30.6                      10.3      376   33.6±9.7      32.1    10.9   175   32.0±9.0     30.5    10.9   0.1070
  Cystatin C, mg/L               234                       0.8±0.3                  0.8                       0.26      377   0.8±0.4       0.8     0.22   175   0.8±0.3      0.7     0.29   0.4652
  Diastolic BP, mm Hg            228                       88.1±16.3                85.0                      20.3      377   87.0±15.1     85.5    17.0   175   86.9±12.8    85.5    17.5   0.9389
  GFR, ml/min/1.73m^2^           234                       95.3±25.1                96.7                      31.2      377   96.1±27.0     95.5    31.5   175   94.1±26.5    92.1    35.3   0.6755
  Systolic BP, mm Hg             228                       131.1±26.0               128.8                     27.8      377   131.1±23.8    126.0   29.5   175   128.2±20.7   126.0   26.5   0.5164
  Urine ACR, mg/g                234                       92.5±559.5               5.0                       14.5      377   105.4±610.4   5.4     14.0   175   62.7±173.7   6.4     13.8   0.3506

BMI - body mass index; BP - blood pressure; GFR - MDRD glomerular filtration rate; ACR - albumin: creatinine ratio; IQR -- inter-quartile range

###### 

Unadjusted *APOL1* associations in the full sample (categorical variables; recessive model)

  Variable, category                                     0/1 *APOL1* risk variants   2 *APOL1* risk variants   Full Sample   P-value                
  ------------------------------------------------------ --------------------------- ------------------------- ------------- --------- ----- ------ --------
  Kidney disease\*, No                                   482                         78.1                      135           21.9      617   78.5   0.6205
  Kidney disease\*, Yes                                  129                         76.3                      40            23.7      169   21.5   
  Hypertension, No                                       346                         76.9                      104           23.1      450   57.7   0.5976
  Hypertension, Yes                                      259                         78.5                      71            21.5      330   42.3   
  Sex, Male                                              249                         79.6                      64            20.4      313   39.8   0.3191
  Sex, Female                                            362                         76.5                      111           23.5      473   60.2   
  Age \< 20 years                                        6                           46.2                      7             53.8      13    1.7    0.0492
  Age 20--30 years                                       60                          74.1                      21            25.9      81    10.3   
  Age 30--40 years                                       93                          80.9                      22            19.1      115   14.6   
  Age 40--50 years                                       159                         76.8                      48            23.2      207   26.3   
  Age 50--60 years                                       268                         78.4                      74            21.6      342   43.6   
  Age ≥ 70 years                                         25                          89.3                      3             10.7      28    3.6    
  Proband-participant age difference: −25 to −15 years   11                          64.7                      6             35.3      17    2.2    0.4650
  Proband-participant age difference: −15 to −5 years    162                         77.1                      48            22.9      210   26.9   
  Proband-participant age difference: −5 to +5 years     240                         80.5                      58            19.5      298   38.2   
  Proband-participant age difference: +5 to +15 years    172                         75.8                      55            24.2      277   29.1   
  Proband-participant age difference: \> +15 years       22                          78.6                      6             21.4      28    3.6    
  MDRD GFR \<60 ml/min/1.73m^2^                          43                          75.4                      14            24.6      57    7.3    0.8250
  MDRD GFR 60--90 ml/min/1.73m^2^                        205                         76.2                      64            23.8      269   34.2   
  MDRD GFR [90]{.ul}--120 ml/min/1.73m^2^                274                         79.0                      73            21.0      347   44.1   
  MDRD GFR ≥120 ml/min/1.73m^2^                          89                          78.8                      24            21.2      113   14.4   
  Urine ACR 0--30 mg/g                                   504                         78.3                      140           21.7      644   81.9   0.1911
  Urine ACR 30--299 mg/g                                 82                          78.8                      22            21.2      104   13.2   
  Urine ACR ≥300 mg/g                                    25                          65.8                      13            34.2      38    4.8    
  Urine ACR \<30 mg/g                                    504                         78.3                      140           21.7      644   81.9   0.4508
  Urine ACR ≥30 mg/g                                     107                         75.4                      35            24.6      142   18.1   
  Urine ACR 0--17 mg/g (Males only)                      179                         80.3                      44            19.7      223   71.3   0.6209
  Urine ACR ≥17 mg/g (Males only)                        70                          77.8                      20            22.2      90    28.7   
  Urine ACR 0--25 mg/g (Females only)                    298                         76.6                      91            23.9      389   82.2   0.9349
  Urine ACR ≥25 mg/g (Females only)                      64                          76.2                      20            23.8      84    17.8   
  Cystatin C \<0.96 mg/L                                 491                         77.9                      139           22.1      630   80.2   0.7853
  Cystatin C ≥0.96 mg/L                                  120                         76.9                      36            23.1      156   19.8   

• Kidney disease defined as an MDRD GFR \<60 ml/min/1.73m^2^ and/or Urine ACR \> 30 mg/g

• GFR -- MDRD glomerular filtration rate; ACR -- albumin: creatinine ratio

###### 

Unadjusted *APOL1* associations in the full sample (continuous variables; recessive model)

  Variable                       0/1 APOL1 risk variants (N=611)   2 APOL1 risk variants (N=175)   P-value                           
  ------------------------------ --------------------------------- ------------------------------- --------- ------- ------- ------- --------
  African ancestry, %            0.78                              0.11                            0.80      0.79    0.09    0.80    0.2974
  Age, yrs                       48.1                              13.3                            49.0      45.6    13.5    48.0    0.0159
  Age relative to proband, yrs   −0.1                              8.9                             0.0       0.1     9.2     1.0     0.7226
  BMI, kg/m^2^                   33.1                              9.4                             31.5      32.0    9.0     30.5    0.1380
  Cystatin C, mg/L               0.8                               0.3                             0.8       0.8     0.3     0.7     0.6054
  Diastolic BP, mm Hg            87.4                              15.6                            85.5      86.9    12.8    85.5    0.9140
  MDRD GFR, ml/min/1.73m^2^      95.8                              26.3                            95.9      94.1    26.5    92.1    0.4325
  Systolic BP, mm Hg             131.1                             24.6                            127.0     128.2   20.7    126.0   0.1525
  Urine ACR mg/g                 100.5                             591.0                           5.2       62.7    173.7   6.4     0.2184

BMI - body mass index; BP - blood pressure; GFR - glomerular filtration rate; ACR - albumin: creatinine ratio

###### 

Multivariate *APOL1* association analyses in the full sample (recessive model)

  Outcome               Model     Estimate   SE        Lower CI   Upper CI   Z        P-value
  --------------------- --------- ---------- --------- ---------- ---------- -------- ---------
  MDRD GFR              1         −1.6947    2.2773    −6.1581    2.7687     −0.74    0.4568
  2                     −3.7055   2.0167     −7.6581   0.2471     −1.84      0.0661   
  3                     −3.8112   2.0378     −7.8052   0.1827     −1.87      0.0614   
  CKD-EPI GFR           1         −1.1306    2.1892    −5.4214    3.1601     −0.52    0.6055
  2                     −3.5187   1.8506     −7.1459   0.1085     −1.9       0.0573   
  3                     −3.6583   1.8696     −7.3226   0.0059     −1.96      0.0504   
  Log urine ACR         1         0.163      0.1431    −0.1174    0.4433     1.14     0.2546
  2                     0.2095    0.1434     −0.0715   0.4905     1.46       0.1439   
  3                     0.2391    0.1435     −0.0422   0.5204     1.67       0.0957   
  Kidney disease        1         0.09       0.2132    −0.328     0.5079     0.42     0.6731
  2                     0.1733    0.2232     −0.2642   0.6107     0.78       0.4376   
  3                     0.2144    0.2246     −0.2258   0.6545     0.95       0.3398   
  Urine ACR ≥30 mg/g    1         0.143      0.2209    −0.29      0.576      0.65     0.5175
  2                     0.2021    0.2265     −0.2418   0.6461     0.89       0.3722   
  3                     0.2422    0.2277     −0.2042   0.6886     1.06       0.2875   
  Urine ACR ≥300 mg/g   1         0.7162     0.3513    0.0277     1.4047     2.04     0.0415
  2                     0.7191    0.3542     0.0249    1.4132     2.03       0.0423   
  3                     0.7607    0.3551     0.0647    1.4568     2.14       0.0322   

MDRD GFR - Modification of Diet in Renal Disease estimated glomerular filtration rate;

ACR -- albumin: creatinine ratio; Kidney disease reflects either urine ACR ≥30 mg/g and/or MDRD GFR \<60 ml/min/1.73 m^2^ Estimate = β coefficient; Z=(Estimate/SE)

Model 1= Ancestry-adjusted; Model 2= Model 1 + age and sex; Model 3= Model 2 + age difference from ESRD in proband
